Medical testing provider Castle Bio raises annual revenue guidance

Castle Biosciences

04/08/2025 21:42

Overview

Castle Biosciences Q2 2025 revenue of $86.2 mln smashes analyst expectations

The medical testing provider raises full-year 2025 revenue guidance to $310-320 mln

Q2 test report volume increased 6% yr/yr

Outlook

Castle Biosciences raises 2025 revenue guidance to $310 mln-$320 mln

Previse acquisition and SciBase collaboration expected to support future growth

Result Drivers

CORE TEST GROWTH - DecisionDx-Melanoma and TissueCypher test volumes increased significantly, driving revenue performance

NON-COVERAGE IMPACT - Revenue affected by Novitas LCD non-coverage of DecisionDx-SCC and discontinuation of IDgenetix

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$86.19 mln
$71.40 mln (9 Analysts)
Q2 Net Income
$4.52 mln
Q2 Operating Expenses
$90.44 mln
Q2 Operating Income
-$4.25 mln
Q2 Pretax Profit
-$143,000


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Castle Biosciences Inc is $36.00, about 59.3% above its August 1 closing price of $14.65

Press Release: ID:nGNX5JTsdW

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)